AZYO:NSD-Aziyo Biologics, Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 12.47

Change

-0.19 (-1.50)%

Market Cap

USD 0.14B

Volume

2.52K

Average Target Price

USD 20.00 (+60.38%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device; and cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. The company also provides FiberCel, ViBone, and OsterGro V that are designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. In addition, it offers contract manufacturing services for various products to corporate customers. The company sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. Aziyo Biologics, Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-22 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology, Inc

-0.77 (-0.12%)

USD47.18B 26.60 98.00
PODD Insulet Corporation

-1.55 (-0.54%)

USD19.09B 2,882.70 179.30
ABMD Abiomed, Inc

+0.76 (+0.22%)

USD15.50B 78.10 58.30
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
BRKR Bruker Corporation

-0.27 (-0.40%)

USD10.18B 65.84 32.31
IART Integra LifeSciences Holdings ..

+0.02 (+0.03%)

USD6.28B 47.36 25.93
TNDM Tandem Diabetes Care, Inc

-0.70 (-0.74%)

USD5.90B N/A N/A
SWAV ShockWave Medical, Inc

+4.83 (+3.15%)

USD5.06B N/A N/A
LIVN LivaNova PLC

+0.10 (+0.12%)

USD4.03B 77.40 N/A
SDC SmileDirectClub, Inc

+0.19 (+1.87%)

USD3.94B N/A N/A

ETFs Containing AZYO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.51% 17% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.51% 17% F 19% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.14B 34% F 26% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 6.33 52% F 27% F
Price / Cash Flow Ratio -10.12 56% F 76% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -419.07% 6% F 2% F
Return on Invested Capital -110.61% 21% F 7% F
Return on Assets -12.54% 57% F 26% F
Debt to Equity Ratio 85.50% 29% F 25% F
Technical Ratios  
Short Ratio 10.25 5% F 5% F
Short Percent 5.14% 46% F 38% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector